Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants - Full Text View

Purpose

Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent pneumococcal conjugate vaccine (7vPnC) and DTaP, Group 3: DTaP alone. Group 3 subjects will also receive catch-up doses of Prevenar (commercial product of Prevenar in Japan) 13vPnC and 7vPnC will be blinded, and DTaP will be open-label. The main purpose of the study is to determine if the immune responses to 13vPnC are comparable to the immune responses to 7vPnC and if the immune responses to 13vPnC given with DTaP are comparable to those induced by DTaP given alone. In addition, the study aims to evaluate the side effects (safety profile) after vaccination of 13vPnC and 7vPnC when given with DTaP in healthy Japanese infants.

Condition	Intervention	Phase
Healthy Subjects	Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP) Biological: 7-valent pneumococcal conjugate vaccine (7vPnC) Biological: DTaP	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention
Official Title:	A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants

Resource links provided by NLM:

MedlinePlus related topics: Diphtheria Tetanus Whooping Cough

Drug Information available for: Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
Percentage of participants achieving predefined antibody threshold >=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).

Secondary Outcome Measures:

Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 Mcg/mL 1 Month After the Toddler Dose [ Time Frame: 1 month after the toddler dose ] [ Designated as safety issue: No ]
Percentage of participants achieving predefined antibody threshold >=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose [ Time Frame: 1 month after the toddler dose ] [ Designated as safety issue: No ]
Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose [ Time Frame: 1 month after the toddler dose ] [ Designated as safety issue: No ]
Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series [ Time Frame: 1 month after the infant series ] [ Designated as safety issue: No ]
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose [ Time Frame: 1 month after the toddler dose ] [ Designated as safety issue: No ]
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose [ Time Frame: 1 month after the toddler dose ] [ Designated as safety issue: No ]
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.

Other Outcome Measures:

Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age) [ Time Frame: Within 7 days after Dose 1 of the infant series ] [ Designated as safety issue: Yes ]
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age) [ Time Frame: Within 7 days after Dose 2 of the infant series ] [ Designated as safety issue: Yes ]
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age) [ Time Frame: Within 7 days after Dose 3 of the infant series ] [ Designated as safety issue: Yes ]
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age) [ Time Frame: Within 7 days after the toddler dose ] [ Designated as safety issue: Yes ]
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age) [ Time Frame: Within 7 days after Dose 1 of infant series ] [ Designated as safety issue: Yes ]
Systemic events (any fever >= 37.5 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age) [ Time Frame: Within 7 days after Dose 2 of infant series ] [ Designated as safety issue: Yes ]
Systemic events (any fever >= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age) [ Time Frame: Within 7 days after Dose 3 of infant series ] [ Designated as safety issue: Yes ]
Systemic events (any fever >= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age) [ Time Frame: Within 7 days after the toddler dose ] [ Designated as safety issue: Yes ]
Systemic events (any fever >= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Enrollment:	551
Study Start Date:	September 2010
Study Completion Date:	November 2011
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Experimental	Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 mL per dose, 4 doses Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP) 0.5 mL per dose, 4 doses
Active Comparator: 2 Active comparator	Biological: 7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL per dose, 4 doses Biological: DTaP 0.5 mL per dose, 4 doses
Active Comparator: 3 Active comparator	Biological: DTaP 0.5 mL per dose, 4 doses

Eligibility

Ages Eligible for Study:	3 Months to 6 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male or female subjects between 3 to 6 months of age at the enrollment.
Available for the entire study period and whose parent/legal guardian can be reached by telephone.
Healthy infant as determined by medical history, physical examination, and judgement of the investigator.

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, or pertussis vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis, bacteremia, osteomyelitis, arthritis).
Infant who is a direct descendant (child, grandchild) of the study site personnel.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01200368

Locations

Japan
Sunrise Children's Clinic
Funabashi, Chiba, Japan
Sotobo Children's Clinic
Isumi-city, Chiba, Japan
Matsuyama Red Cross Hospital
Matsuyama-city, Ehime, Japan
Fukazawa Pediatric Clinic
Higashi-ku, Fukuoka-city, Fukuoka, Japan
National Hospital Organization Fukuyama Medical Center
Fukuyama, Hiroshima, Japan
National Hospital Organization Kure Medical Center
Kure, Hiroshima, Japan
Furuta Children's Clinic
Sapporo, Hokkaido, Japan
Watanabe Pediatric Allergy Clinic
Sapporo, Hokkaido, Japan
Tenshi Hospital
Sapporo, Hokkaido, Japan
Motomachi pediatric clinic
Sapporo, Hokkaido, Japan
Nakata pediatric clinic
Sapporo, Hokkaido, Japan
Yoshimoto Pediatrist Clinic
Kikuchi-gun, Kumamoto, Japan
Shiroko Clinic
Suzuka, Mie, Japan
National Mie Hospital
Tsu, Mie, Japan
National hospital Organization Mie Chuou Medical Center
Tsu, Mie, Japan
Children's Enomoto Clinic
Kumagaya, Saitama, Japan
Shibuya Clinic
Kumagaya-city, Saitama, Japan
Sakiyama Children's Clinic
Fuchu, Tokyo, Japan
Okawa Children and Family Clinic
Ota-ku, Tokyo, Japan
Seijo Sasamoto Pediatric And Allergy Clinic
Setagaya-ku, Tokyo, Japan
National Center for Child Health and Development
Setagaya-ku, Tokyo, Japan
Miyata Pediatric Clinic
Tachikawa-shi, Tokyo, Japan
Maehara Pediatric Clinic
Tama, Tokyo, Japan
Childrens Clinic of Kose
Kofu, Yamanashi, Japan
Medical Corporation Bunpoukai Amemiya Clinic
Koushu-shi, Yamanashi, Japan
Medical Corporation Seijinkai Takei Clinic
Tsuru-shi, Yamanashi, Japan
National Hospital Organization Fukuoka National Hospital
Fukuoka, Japan
Harada Clinic
Fukuoka, Japan
Medical Corporation Seiaikai Seguchi Pediatric Clinic
Kumamoto, Japan
Hattori Pediatric Clinic
Kumamoto, Japan
Medical Corporation Oukakai Sakuranbo Kodomo Clinic
Kumamoto, Japan
Momotaro Clinic
Okayama, Japan

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT01200368 History of Changes
Other Study ID Numbers:	B1851056, B1851056
Study First Received:	August 31, 2010
Results First Received:	September 12, 2012
Last Updated:	September 12, 2012
Health Authority:	Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Pfizer:

vaccine
pneumococcal conjugate

ClinicalTrials.gov processed this record on May 23, 2013